Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Samia Mora, M.D.

TitleAssistant Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women
Prevntive Medicine - 3rd Fl
900 Commonwealth Ave
Boston MA 02215
Phone617/278-0783
Fax617/264-9194

 Mentoring 
 completed student projects
A National Interactive Web-Based Physical Activity Intervention in Women: Evaluation of Choose to Move 2006-2007
Summer, 06/29/09 - 08/14/09
Angina with “Normal” Coronary Arteries (Cardiac Syndrome X): A Benign Prognosis?
Summer, 06/11/07 - 08/13/07

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Thomas D, Al-Mallah M, Govindarajulu U, Forman DE, Mora S, Di Carli MF, Dorbala S. Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. Eur Heart J. 2013 Mar 28.
    View in: PubMed
  2. Mazer NA, Giulianini F, Paynter NP, Jordan P, Mora S. A Comparison of the Theoretical Relationship between HDL Size and the Ratio of HDL Cholesterol to Apolipoprotein A-I with Experimental Results from the Women's Health Study. Clin Chem. 2013 Feb 20.
    View in: PubMed
  3. Khera AV, Mora S. Fasting for lipid testing: is it worth the trouble?: comment on "fasting time and lipid levels in a community-based population". Arch Intern Med. 2012 Dec 10; 172(22):1710-1.
    View in: PubMed
  4. Khera AV, Mora S. Fasting for lipid testing: Is it worth the trouble? Arch Intern Med. 2012 Dec 10; 172(22):1710-2.
    View in: PubMed
  5. Ndumele CE, Matsushita K, Astor B, Virani SS, Mora S, Williams EK, Hoogeveen RC, Blumenthal RS, Sharrett AR, Ballantyne CM, Coresh J. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: The ARIC Study. Eur J Prev Cardiol. 2012 Oct 29.
    View in: PubMed
  6. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012 Aug 7; 60(6):508-16.
    View in: PubMed
  7. Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2012 Apr 24; 59(17):1521-8.
    View in: PubMed
  8. Lieber SB, Redberg RF, Blumenthal RS, Gandhi A, Robb KJ, Mora S. A national interactive web-based physical activity intervention in women, evaluation of the american heart association choose to move program 2006-2007. Am J Cardiol. 2012 Jun 15; 109(12):1754-60.
    View in: PubMed
  9. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24; 125(16):1979-87.
    View in: PubMed
  10. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012 Mar 28; 307(12):1302-9.
    View in: PubMed
  11. Mora S. Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels. Evid Based Med. 2012 Aug; 17(4):133-4.
    View in: PubMed
  12. Mora S. Aspirin therapy in primary prevention: comment on "effect of aspirin on vascular and nonvascular outcomes". Arch Intern Med. 2012 Feb 13; 172(3):217-8.
    View in: PubMed
  13. Graham G, Ketlogetswe K, Campbell CY, Musunuru K, Mora S, Blumenthal RS. Use of high sensitivity C-reactive protein for risk assessment. In: Baliga RR and Cannon CP, editors. Dyslipidemia. Oxford University Press, NY, NY; 67-86. 2012.
  14. Mora S, Buring JE, Ridker PM, Cui Y. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med. 2011 Dec 6; 155(11):742-50.
    View in: PubMed
  15. Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, Ahmad T, Mora S, Kaakinen M, Sandholt CH, Holzapfel C, Autenrieth CS, Hyppönen E, Cauchi S, He M, Kutalik Z, Kumari M, Stancáková A, Meidtner K, Balkau B, Tan JT, Mangino M, Timpson NJ, Song Y, Zillikens MC, Jablonski KA, Garcia ME, Johansson S, Bragg-Gresham JL, Wu Y, van Vliet-Ostaptchouk JV, Onland-Moret NC, Zimmermann E, Rivera NV, Tanaka T, Stringham HM, Silbernagel G, Kanoni S, Feitosa MF, Snitker S, Ruiz JR, Metter J, Larrad MT, Atalay M, Hakanen M, Amin N, Cavalcanti-Proença C, Grøntved A, Hallmans G, Jansson JO, Kuusisto J, Kähönen M, Lutsey PL, Nolan JJ, Palla L, Pedersen O, Pérusse L, Renström F, Scott RA, Shungin D, Sovio U, Tammelin TH, Rönnemaa T, Lakka TA, Uusitupa M, Rios MS, Ferrucci L, Bouchard C, Meirhaeghe A, Fu M, Walker M, Borecki IB, Dedoussis GV, Fritsche A, Ohlsson C, Boehnke M, Bandinelli S, van Duijn CM, Ebrahim S, Lawlor DA, Gudnason V, Harris TB, Sørensen TI, Mohlke KL, Hofman A, Uitterlinden AG, Tuomilehto J, Lehtimäki T, Raitakari O, Isomaa B, Njølstad PR, Florez JC, Liu S, Ness A, Spector TD, Tai ES, Froguel P, Boeing H, Laakso M, Marmot M, Bergmann S, Power C, Khaw KT, Chasman D, Ridker P, Hansen T, Monda KL, Illig T, Järvelin MR, Wareham NJ, Hu FB, Groop LC, Orho-Melander M, Ekelund U, Franks PW, Loos RJ. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011 Nov; 8(11):e1001116.
    View in: PubMed
  16. Paynter NP, Sesso HD, Conen D, Otvos JD, Mora S. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem. 2011 Aug; 57(8):1178-87.
    View in: PubMed
  17. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011 Mar-Apr; 5(2):105-13.
    View in: PubMed
  18. Ahmad T, Lee IM, Paré G, Chasman DI, Rose L, Ridker PM, Mora S. Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care. 2011 Mar; 34(3):675-80.
    View in: PubMed
  19. Shah AM, Mora S. Exercise treadmill stress testing with and without imaging. Prevention of Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. 2011; 477-490.
  20. Ahmad T, Chasman DI, Mora S, Paré G, Cook NR, Buring JE, Ridker PM, Lee IM. The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. Am Heart J. 2010 Dec; 160(6):1163-9.
    View in: PubMed
  21. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010 Jul 31; 376(9738):333-9.
    View in: PubMed
  22. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010 Aug; 56(8):1252-60.
    View in: PubMed
  23. Weiss SA, Blumenthal RS, Sharrett AR, Redberg RF, Mora S. Exercise blood pressure and future cardiovascular death in asymptomatic individuals. Circulation. 2010 May 18; 121(19):2109-16.
    View in: PubMed
  24. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010 May; 59(5):1153-60.
    View in: PubMed
  25. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 Mar 9; 121(9):1069-77.
    View in: PubMed
  26. Ahmad T, Mora S. Providing patients with global cardiovascular risk information: is knowledge power? Arch Intern Med. 2010 Feb 8; 170(3):227-8.
    View in: PubMed
  27. Musunuru K, Blumenthal RS, Mora S. C-reactive protein and cardiovascular disease. The clinical utility of C-reactive protein in cardiovascular disease. 2010; 157-174.
  28. Musunuru K, Mora S. The Johns Hopkins Textbook of Dyslipidemia. Clinical Utility of Inflammatory Markers. 2010; 183-195.
  29. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan S, Mälarstig A, Ordovas JM, Ripatti S, Parker AN, Miletich JP, Ridker PM. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009 Nov; 5(11):e1000730.
    View in: PubMed
  30. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol. 2009 Sep 29; 54(14):1364-405.
    View in: PubMed
  31. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. Circulation. 2009 Sep 29; 120(13):1296-336.
    View in: PubMed
  32. Moukarbel GV, Shah AM, Tinnemore A, Mora S. Biphasic pulmonary regurgitation. Echocardiography. 2009 Jul; 26(6):720-3.
    View in: PubMed
  33. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation. 2009 May 5; 119(17):2396-404.
    View in: PubMed
  34. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009 May; 55(5):888-94.
    View in: PubMed
  35. Mora S. Aspirin therapy in women: back to the ABCs. Circ Cardiovasc Qual Outcomes. 2009 Mar; 2(2):63-4.
    View in: PubMed
  36. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009 Feb 24; 119(7):931-9.
    View in: PubMed
  37. Mora S. Circulation: Cardiovascular Quality and Outcomes. Aspirin Therapy in Women: Back to the ABCs. 2009; 2:63-64.
  38. Campbell CY, Musunuru K, Mora S, Blumenthal RS. Clinical Lipidology: A Companion to Braunwald’s Heart Disease. Use of high sensitivity C-reactive protein for risk assessment. 2009; 158-166.
  39. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem. 2009 Feb; 55(2):219-28.
    View in: PubMed
  40. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ, Willerson JT, Desai MY, Davidson MH, Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35.
    View in: PubMed
  41. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008 Sep 2; 118(10):993-1001.
    View in: PubMed
  42. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007 Nov 6; 116(19):2110-8.
    View in: PubMed
  43. Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J. 2007 Dec; 28(23):2937-43.
    View in: PubMed
  44. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18; 298(3):309-16.
    View in: PubMed
  45. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC, O'Leary DH, Saad MF, Tsai MY, Sharrett AR. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007 May; 192(1):211-7.
    View in: PubMed
  46. Becker DM, Mora S, Goff DC. Biomarkers for prediction of cardiovascular events. N Engl J Med. 2007 Apr 5; 356(14):1473; author reply 1474-5.
    View in: PubMed
  47. Zee RY, Mora S, Cheng S, Erlich HA, Lindpaintner K, Rifai N, Buring JE, Ridker PM. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem. 2007 May; 53(5):845-51.
    View in: PubMed
  48. Redberg RF, Mora S, Barbour DJ. American College of Obstetricians and Gynecologists Clinical Updates in Women’s Health Care. Chest pain and heart disease. 2007; VI(1):1-83.
  49. Mora S, Wu KC. The Johns Hopkins Manual of Cardiothoracic Surgery. Echocardiography in cardiac surgery. 2007; 943-68.
  50. D'Amore S, Mora S. Gender-specific prediction of cardiac disease: importance of risk factors and exercise variables. Cardiol Rev. 2006 Nov-Dec; 14(6):281-5.
    View in: PubMed
  51. Schneider JG, Tompkins C, Blumenthal RS, Mora S. The metabolic syndrome in women. Cardiol Rev. 2006 Nov-Dec; 14(6):286-91.
    View in: PubMed
  52. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006 Aug 1; 114(5):381-7.
    View in: PubMed
  53. Reynolds SS, Yanek LR, Vaidya D, Mora S, Moy TF, Saudek CD, Becker LC, Becker DM. Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. Diabetes Res Clin Pract. 2006 Dec; 74(3):267-73.
    View in: PubMed
  54. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006 Mar 22; 295(12):1412-9.
    View in: PubMed
  55. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006 Jan 16; 97(2A):33A-41A.
    View in: PubMed
  56. Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation. 2005 Sep 13; 112(11):1566-72.
    View in: PubMed
  57. Mora S, Yanek LR, Moy TF, Fallin MD, Becker LC, Becker DM. Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation. 2005 Apr 19; 111(15):1871-6.
    View in: PubMed
  58. Mora S, Redberg RF, Cui Y, Whiteman MK, Flaws JA, Sharrett AR, Blumenthal RS. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA. 2003 Sep 24; 290(12):1600-7.
    View in: PubMed
  59. Mora S, Kershner DW, Vigilance CP, Blumenthal RS. Coronary Artery Disease in Postmenopausal Women. Curr Treat Options Cardiovasc Med. 2001 Feb; 3(1):67-79.
    View in: PubMed
  60. Mora S, Blumenthal RS. Mild hypercholesterolemia and premature coronary artery disease. Cardiol Rev. 2001; 18:33-34.
  61. Mora S, Stafford RS, Pasternak RC. Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. Am J Cardiol. 2000 Oct 1; 86(7):783-5, A9.
    View in: PubMed
  62. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Invest. 1999; 48(2):127-32.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Mora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (212) concept(s)
_
Co-Authors
See all (23) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_